1. |
中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识. 中华神经科杂志, 2017, 50(2): 91-98.
|
2. |
Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology, 2010, 9(1): 67-76.
|
3. |
Poliak S, Gollan L, Martinez R, et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron, 1999, 24(4): 1037-1047.
|
4. |
Lu Z, Reddy M, Liu J, et al. Molecular architecture of contactin-associated protein-like 2 (CNTNAP2) and its interaction with contactin 2 (CNTN2). Journal of Biological Chemistry, 2016, 291(46): 24133-24147.
|
5. |
Sonderen AV, Schreurs M, Wirtz PW, et al. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time. Autoimmunity Reviews, 2016, 15(10): 970-974.
|
6. |
P Jesús, Frank L, Francesco M, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain, 2015, 138(1): 94-109.
|
7. |
V Sonderen, Agnes, Arino, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology, 2016, 87(18): 521-522.
|
8. |
Sonderen AV, Petit-Pedrol M, Dalmau J, et al. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nature Reviews Neurology, 2017, 13(5): 290-301.
|
9. |
Gadoth A, Pittock SJ, D Dubey, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG positive patients. Annals of Neurology, 2017, 82(1): 79-92.
|
10. |
Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Annals of Neurology, 2018, 83(1): 40-51.
|
11. |
Bien CG, Mirzadjanova Z, Baumgartner C, et al. Anti‐contactin‐associated protein‐2 encephalitis: relevance of antibody titres, presentation and outcome. European Journal of Neurology, 2016, 24(1): 175-186.
|